Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Eletriptan.

M J Gawel1, N N Grujich

  • 1Division of Neurology, Sunnybrook & Women's College Health Sciences Centre, University of Toronto, Toronto, ON, Canada. marek.gawel@swchsc.on.ca

Expert Opinion on Investigational Drugs
|January 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

New Classification of Headache: A more accurate method of diagnosis.

Canadian family physician Medecin de famille canadien·2011
Same author

Clinical features and pharmacological treatment of migraine patients referred to headache specialists in Canada.

Cephalalgia : an international journal of headache·2006
Same author

Comparison of butorphanol nasal spray and fiorinal with codeine in the treatment of migraine.

Headache·2004
Same author

A systematic review of the use of triptans in acute migraine.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2001
Same author

Oral zolmitriptan is effective in the acute treatment of cluster headache.

Neurology·2000
Same author

The new triptans.

The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique·1999
Same journal

Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.

Expert opinion on investigational drugs·2026
Same journal

Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights.

Expert opinion on investigational drugs·2026
Same journal

Odronextamab: a bispecific antibody for follicular lymphoma.

Expert opinion on investigational drugs·2026
Same journal

Evaluating the investigational drug landscape for <i>ESR1</i>-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.

Expert opinion on investigational drugs·2026
Same journal

Darigabat and subtype-selective GABA-A modulation: pharmacology, clinical development, and translational challenges.

Expert opinion on investigational drugs·2026
Same journal

Safety, tolerability, and pharmacokinetics of HL-300, a novel topical pan-JAK inhibitor, in healthy Chinese adults: a first-in-human, randomized, double-blind, placebo-controlled phase I trial.

Expert opinion on investigational drugs·2026
See all related articles

Eletriptan offers faster migraine relief than sumatriptan due to rapid absorption. This serotonin agonist (5-HT1B/1D) provides superior headache response and symptom relief with high patient acceptance.

Area of Science:

  • Pharmacology
  • Neurology
  • Gastroenterology

Background:

  • Eletriptan is an oral anti-migraine medication belonging to the triptan class.
  • It functions as a potent serotonin 5-HT1B/1D receptor agonist.
  • Eletriptan is prescribed for the acute management of migraine headaches.

Purpose of the Study:

  • To compare the efficacy and patient acceptance of oral eletriptan versus oral sumatriptan.
  • To evaluate the pharmacokinetic properties, including absorption and bioavailability, of eletriptan.
  • To assess the onset of action, response rates, and symptom relief associated with eletriptan treatment.

Main Methods:

  • Comparative clinical studies involving oral eletriptan and sumatriptan.
  • Assessment of pharmacokinetic parameters such as bioavailability and absorption rates.

Related Experiment Videos

  • Evaluation of headache response, pain-free rates, and symptom relief at specified time intervals.
  • Collection of patient acceptability data.

    • Main Results:

    • Eletriptan exhibits rapid oral absorption and 50% bioavailability, significantly higher than sumatriptan's 14%.
    • Eletriptan's lipophilicity contributes to faster absorption and quicker onset of action.
    • Eletriptan 80 mg demonstrated superiority over sumatriptan 100 mg in onset of action, headache response, and pain-free rates at 1-2 hours.
    • A modest increase in adverse events for eletriptan was offset by a high patient acceptability rating of 84%.

    Conclusions:

    • Oral eletriptan is a highly effective acute treatment for migraine headaches.
    • Eletriptan offers a faster onset of action and superior efficacy compared to sumatriptan.
    • The drug is well-tolerated and highly accepted by patients, making it a valuable therapeutic option.